
        <!DOCTYPE html>
    <html lang="ja">
    <style>
    body
    {
        color: black;
        background-color: white;
    }
    div{
        font-size: 14px;
    }
    span
    {
        font-size: 18px;
    }
    #grad1{
        background: linear-gradient(transparent 60%,#99e4f1 30%);
        font-size: 18px;
        font-weight: bold;
    }
    #grad2{
        background: linear-gradient(transparent 60%,#fda1a1 30%);
        font-size: 18px;
        font-weight: bold;
    }

    </style>

    <head>
        <meta charset="UTF-8">
        <title>105-338</title>
    </head>

    <body>
        <h1>
        <a href="./105_337.html" rel="external" title="prev">≪</a>
        105-338
        <a href="./105_339.html" rel="external" title="next">≫</a>
        </h1>
        <div class='problem'>
            <p>
                <span id="grad1">　問題文　</span>
            </p>
            <p>
                <p>59歳女性。以下の処方薬と検査値の記載された処方箋を薬局に持参した。この患者は約1年間、同一の処方内容で外来治療を受けており、前回までの検査値は基準値内を推移していたが、今回の検査で異常が認められた。</p>
<p><img alt="" class="alignnone size-full wp-image-21222" height="172.2" loading="lazy" sizes="(max-width: 580px) 100vw, 580px" src="data:;base64,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" width="406.0"/></p>
<p>今回の検査値：Hb 12.4g/dL、Plt 23.0×10<sup>4</sup>/μL、Na 140mEq/L、Cl 100mEq/L、K 5.8mEq/L、血清クレアチニン値 0.78mg/dL、AST 22IU/L、ALT 20IU/L、HbA1c 5.2%(NGSP値)、LDL-C 105mg/dL、TG(トリグリセリド) 115mg/dL</p>
<p>今回の検査値の異常と関連性が高く、疑義照会すべき優先順位の高い医薬品はどれか。2つ選べ。</p>
<ol><li>エプレレノン錠</li><li>リナグリプチン錠</li><li>ピタバスタチンカルシウム錠</li><li>カルベジロール錠</li><li>ペリンドプリルエルブミン錠</li></ol>    
            </p>
        </div>
        <hr>

        <input type="button" value="check ans" onclick="toggle_switch()"/>
        
        <div id='toggle'>
        <div class='answer'>
            <p>
                <span id="grad2">　解答　　</span>
            </p>
            <p>
            1, 5
            </p>
        </div>
        <div class='description'>
            <p>
                <span id="grad2">　解説　　</span>
            </p>
            <p>K 値の基準値目安は まず大雑把に ４ ± 0.5 ぐらいの範囲で、上は 5.0 ぐらいまで、です。高 K と判断します。</p>
<p>エプレレノン（セララ）は選択的アルドステロンブロッカーです。K 保持性利尿薬です。高 K 血症が見られるため、疑義照会すべきと考えられます。</p>
<p>リナグリプチン（トラゼンタ）は、◯◯グリプチンなので、DPP－4（Dipeptidyl Peptidase-4<b>）</b>選択的阻害薬です。</p>
<p>ピタバスタチン（リバロ）は、スタチン系、HMG – CoA 還元酵素阻害剤です。</p>
<p>カルベジロールは、α,β 遮断薬です。</p>
<p>ペリンドプリル（コバシル）は、持続性組織 ACE 阻害剤です。レニンーアンギオテンシン系の抑制により、高 K 血症を引き起こす可能性があるため、疑義照会すべきと考えられます。</p>
<p>以上より、正解は 1,5 です。</p>
            </p>
        </div>
        </div>
    </body>
    <script>
    document.getElementById("toggle").style.display="none";
    function toggle_switch(){
        var x = document.getElementById("toggle");
        if (x.style.display=="block"){
            x.style.display="none";
        }
        else{
            x.style.display="block";
        }
    }
    </script>
    